[Aminosalicylates and aspirin for colonic cancer: from anti-inflammatory to antineoplastic drugs?].
The aim of this article is to review potential antineoplastic properties of anti-inflammatory compounds commonly used in various inflammatory diseases such as aminosalicylates, aspirin and other nonsteroidal drugs. Starting from experimental and epidemiologic evidence showing prophylaxis and/or tumor regression/suppression, specific antineoplastic actions especially the inhibition of cyclooxygenase-(COX)dependent and COX-independent steps including the role of transcription factor (NFkappaB) in the cell cycle regulation are reviewed. In addition other mechanisms by which these drugs may exert antitumor effects, also may be important such as induction of apoptosis of cancer cells and/or inhibition of potentially carcinogenic oxidative DNA damage. Based on this knowledge potential clinical implications are discussed.
Allgayer
H
H
Abteilung Krebsnachsorge, Rehaklinik Ob der Tauber der LVA Württemberg, Akademisches Lehrkrankenhaus, Universität Heidelberg.
Tillmann
T
T
Hombach
A
A
Kruis
W
W
Pohl
C
C
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D017209:Apoptosis / Q000187:drug effects; D001241:Aspirin / Q000627:therapeutic use*; D003110:Colonic Neoplasms / Q000188:drug therapy*; D004249:DNA Damage; D006801:Humans; D019804:Mesalamine / Q000627:therapeutic use*; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D019804:Mesalamine; D001241:Aspirin
Aminosalizylate und Aspirin bei Kolonkarzinomen: vom Entzündungshemmer zum Tumorprophylaktikum?